Novo Nordisk (NYSE: NVO) shares surged 10% in premarket trading after the FDA fast-tracked its obesity drug Amycretin,
Top News
-
Abet Global Delivers Professional-Grade MT5 Power with Low Barriers and Full Support
-
Abet Global Brings High-Tech MT5 Forex Trading to Indian Traders
-
Mark Walter Acquires Majority Stake in Lakers for Historic $10B as Jeanie Buss Stays On as Governor
-
Ethical Forex Meets Innovation: Why UAE Traders Choose Abet Global
-
Middle East Escalation Sends Oil Above $75, Fueling Global Inflation Risk
